Loading...
•
Dec 31, 2024
Absci Q4 2024 Earnings Report
Absci reported fourth-quarter results with increased revenue and higher research and development spending, leading to a larger net loss compared to the prior year.
Key Takeaways
Absci generated $0.7 million in revenue during Q4 2024, up from $0.3 million the previous year. Increased investments in R&D and continued operational activities led to a net loss of $29.0 million, as the company advances its pipeline and AI-driven drug creation platform.
Revenue rose to $0.7 million in Q4 2024, more than doubling from Q4 2023.
R&D expenses increased to $18.4 million due to advancing internal programs.
Net loss widened to $29.0 million compared to $23.5 million in Q4 2023.
Cash and short-term investments stood at $112.4 million, funding operations into the first half of 2027.
Absci
Absci
Absci Revenue by Segment
Revenue by Segment
Partner program Revenue
CapyFin.com Forward Guidance
Absci expects to advance key programs into clinical development in 2025 and continue signing additional drug creation partnerships.
Positive Outlook
- ABS-101 expected to initiate Phase 1 studies in the first half of 2025.
- ABS-201 Phase 1 trial anticipated in early 2026 targeting androgenic alopecia.
- Strong strategic collaboration with AMD including a $20 million investment.
- Continued expansion of drug creation partnerships with biotech and pharma companies.
- Cash position sufficient to fund operations into the first half of 2027.
Challenges Ahead
- Increasing research and development expenses impacting profitability.
- Higher stock compensation costs adding to SG&A expenses.
- Potential delays in clinical milestones for ABS-101 and ABS-201.
- Market volatility could affect equity investments and funding strategies.
- Ongoing operational losses expected as development programs scale up.